EC approves Pyrukynd for adult alpha- or beta-thalassemia

The European Commission has approved Agios’ Pyrukynd (mitapivat) for adults with anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia, giving the oral pyruvate kinase activator a new EU indication and orphan medicinal product designation. The decision follows a positive CHMP opinion and is based on the Phase 3 ENERGIZE and ENERGIZE-T programs. Agios said the approval makes Pyrukynd the only medicine approved across all EU member states for this broad adult thalassemia population. Outside the U.S., the drug will continue to use the Pyrukynd brand name; in the U.S., the same molecule was approved in December 2025 for adult thalassemia under the brand name Aqvesme. (investor.agios.com)

Why it matters: For veterinary professionals tracking translational medicine, rare disease therapeutics, and the hematology pipeline, this is another example of a metabolism-targeted oral therapy moving into broader real-world use. The EU label covers both transfusion-dependent and non-transfusion-dependent adult patients, which is notable in a category where treatment options can be fragmented by disease subtype and care setting. Phase 3 data in non-transfusion-dependent disease showed hemoglobin benefit and a manageable adverse-event profile, while U.S. regulatory materials also flagged hepatocellular injury concerns that led to a REMS requirement there, underscoring how regional safety management can diverge even for the same product. (sciencedirect.com)

What to watch: Next comes country-level reimbursement and access work across Europe, led with commercial partner Avanzanite Bioscience, which will determine how quickly eligible patients can actually start treatment. (via.tt.se)